Both free and EV-associated Gal3 increase pathogenic tau accumulation in recipient cells, but whether these forms act through distinct mechanisms or cellular targets remains unclear. This distinction could inform more precise therapeutic strategies targeting specific Gal3 forms. Gap type: unexplained_observation Source paper: Galectin-3 aggravates microglial activation and tau transmission in tauopathy. (2024, The Journal of clinical investigation, PMID:37988169)
Landscape Summary: What distinguishes free versus EV-associated Gal3 in promoting pathogenic tau accumulation? is a 0.84 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What distinguishes free versus EV-associated Gal3 in promoting pathogenic tau accumulation? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: